P. Mcmanus et al., COMPLIANCE WITH RESTRICTIONS ON THE SUBSIDIZED USE OF PROTON PUMP INHIBITORS IN AUSTRALIA, British journal of clinical pharmacology, 46(4), 1998, pp. 409-411
Aims To determine among a cohort of patients newly dispensed a prescri
ption for a proton pump inhibitor (PPI) the extent of prior use of oth
er less expensive agents such as antacids and Hz-receptor antagonists
as evidence of a 'stepped care' approach to peptic ulcer and oesophage
al disease. Methods A retrospective drug utilization study was conduct
ed within the Pharmaceutical Benefits Scheme (PBS) claims database in
Australia. A cohort of social security recipients, who received approv
al for PPI supply in the month of October 1996, had no prior PPI appro
val in the previous 18 months and went on to have the drug dispensed,
was assembled. This group of 'new PPI starters' was then examined for
supply of less expensive prescription medicines to treat peptic ulcer
and oesophageal disease in the 12 months prior to obtaining their PPI
approval. Results In a cohort of 4554 defined new PPI users, 1205 (26.
5%) showed no use of H-2-receptor antagonists, antacids, cisapride, cy
toprotectants or antiregurgitants in the 12 month period prior to comm
encing the PPI. The major reason for use given by prescribers for PBS
supply was 'severe refractory ulcerating oesophagitis' . Conclusions S
ubsidized supply is sun-entry restricted on cost-effectiveness grounds
to refractory peptic ulcer disease or severe oesophageal disease. Des
pite this, utilization and epidemiological data suggest that there is
widespread leakage of use outside these indications particularly to le
ss severe forms of oesophageal disease. This patient tracking study ha
s shown within the PBS database that around a quarter of the patients
are treated directly with a PPI without being prescribed less expensiv
e agents at least in the preceding 12 months.